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The nephrologist’s role in the management of calcium-phospho- While the importance of nephrologist care for patients
rus metabolism in patients with chronic kidney disease. with end-stage renal disease (ESRD) is evident, their
Background. In patients with chronic kidney disease (CKD), role in the care of patients with chronic kidney diseasetimely referral to a nephrologist has been shown to improve
(CKD) is only vaguely defined. A growing body of litera-outcomes, but the specific care measures mediating these supe-
ture has demonstrated that timely nephrologist referralrior outcomes have not been sufficiently described.
Methods. In a cohort of 3014 patients with CKD, we evalu- of patients with CKD is associated with higher quality
ated whether they had any indicators of calcium-phosphorus of care during the transition from CKD to renal replace-
metabolism management prior to renal replacement therapy
ment therapy (RRT) [1–6], and with improved outcomes(RRT). These included measurement of parathyroid hormone
on RRT [7–12]. However, none of these studies has de-(PTH) or vitamin D metabolites, or receipt of calcitriol or
calcium-containing phosphate binders (CCPB) prior to RRT. fined the specific measures nephrologists initiate that led
Control patients without such care were selected by risk-set to these improved outcomes.
matching. We used multivariate conditional logistic regression Several aspects of the care of patients with CKD cananalysis to test whether use of these interventions was associ-
be speculated to mediate the better outcomes seen withated with prior nephrologist consultation. We then used Cox
early nephrologist care: better assessment and manage-proportional hazards models to assess whether implementation
of such care was associated with differences in 1-year mortality ment of renal anemia, blood pressure, malnutrition, or
once RRT was instituted. disturbances of the calcium-phosphorus metabolism.
Results. Only 3.4% of CKD patients had their PTH assessed This study focuses on the latter aspect of CKD care.prior to RRT, and 0.3% had vitamin D status measured. Use of
Changes in calcium-phosphorus metabolism occur rel-calcitriol (12.2%) and CCPBs (16%) was slightly more prevalent.
Seeing a nephrologist was highly associated with use of the tests atively early during the course of CKD [13] and manifest
and drugs studied (odds ratio, 1.28 to 6.46; all P values 0.001), themselves in hyperparathyroidism and decreased levels
but care by generalists or other specialists was not. Manage- of 1,25-dihydroxyvitamin D [14–17], changes which can
ment of calcium-phosphorus metabolism was independently
lead to renal bone disease [18]. A high calcium-phospho-associated with a 35% decreased likelihood of death (hazards
rus product is associated with artherosclerosis, valvularratio0.65; 95%CI, 0.51 to 0.84) in the first year of RRT.
Conclusion. Improvements in management of calcium- and extravascular calcification [19, 20], and higher levels
phosphorus metabolism in patients with CKD are attributable of intact parathyroid hormone (iPTH) are associated
to nephrologist care and appear to mediate the survival benefit with an increased mortality risk [21, 22].seen in patients who see a nephrologist relatively early in the
While generalists rarely see patients with such distur-course of their CKD.
bances in calcium-phosphorus metabolism, nephrolo-
gists are trained to deal with such problems as part of
their subspecialty education [23]. Management of abnor-
mal calcium-phosphorus metabolism is challenging and
may involve not only measurement of serum levels of
calcium and inorganic phosphorus, but also assessmentKey words: late referral, hyperparathyroidism, vitamin D, quality of
care, health policy, outcomes research. of iPTH levels, vitamin D, and its metabolites. Once
this is done, dietary recommendations and therapeuticReceived for publication October 4, 2002
interventions can be implemented and monitored to pre-and in revised form November 27, 2002
Accepted for publication January 2, 2003 vent the downstream consequences of secondary hyper-
parathyroidism [24]. The two main interventions for 2003 by the International Society of Nephrology
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management of such calcium-phosphate disturbances are these patients during the study period. This made it possi-
ble to identify all diagnoses assigned to these patientsphosphorus binders to restrict the intestinal uptake of
inorganic phosphorus, and oral supplementation of vita- by all clinicians who cared for them, including specific
renal diagnoses (polycystic kidney disease, diabetic ne-min D, or its precursor [25].
Aluminum-containing phosphorus binders are also ef- phropathy) as well as comorbidities such as hyperten-
sion, diabetes, congestive heart failure, coronary arteryfective, but can lead to aluminum overload and toxicity,
which is associated with microcytic anemia, osteomalacia, disease, and other relevant conditions. Because of the
expected high collinearity between diabetes and diabeticand encephalopathy [25]. Therefore, several inorganic cal-
cium salts, mostly calcium carbonate and calcium acetate, nephropathy, we decided to include presence or absence
of diabetes in all models.have become the treatment of choice for the hyperphos-
phatemia associated with CKD [26–28]. However, such In the whole cohort (N 3014), we searched for medi-
cal claims containing the Physician’s Current Proceduralmedications may pose the risk of hypercalcemia and
excess calcification, especially in the presence of concur- Terminology (CPT-4) codes for laboratory blood tests
measuring (1) levels of iPTH (CPT-4: 83970), (2) vitaminrent vitamin D therapy. To address this, synthetic noncal-
cemic compounds (e.g., sevelamer hydrochloride) have D metabolites (CPT-4: 82306, 82307, 82652) prior to onset
of RRT, (3) all filled prescriptions for CCPBs (calciumbeen developed [29].
Vitamin D deficiency is treated by oral supplementa- carbonate, calcium acetate), and (4) calcitriol and related
compounds, using the respective National Drug Codetion with either 1,25-dihydroxyvitamin D (calcitriol),
its precursor 1-hydroxyvitamin D (alfacalcidol), ergo- (NDC) codes [32] in the subgroup of patients receiving
comprehensive drug benefits through the New Jerseycalciferol, or doxercalciferol [30]. Alphacalcidol is cur-
rently not marketed in the United States, and doxercal- Medicaid or PAAD programs (N  1004). We then
conducted four independent sets of analysis for each ofciferol was not available during the time of the study.
Intravenous formulations are available, but typically the indicators of pre-ESRD calcium-phosphate metabo-
lism care (numbers 1 to 4). In each patient with a givenused only in patients on RRT.
test or filled prescription ( case), the earliest procedureTo evaluate the role of nephrologists in managing this
code was labeled as the index claim, and the number ofspecific domain of care for patients with CKD, we sought
days prior to RRT was recorded. Next, we identified upto test whether such management occurred more fre-
to 5 CKD controls who had not received the correspond-quently in patients seen by a nephrologist controlling
ing laboratory test or filled the prescription at the samefor other health care utilization patterns as well as demo-
number of days prior to RRT and matched them for agegraphic characteristics and renal and nonrenal comorbid-
with each case (risk-set matching) [33]. In each risk setities. The interventions studied were assessment of iPTH,
(1 case,5 controls), we assessed whether these patientsmeasurement of serum levels of vitamin D and/or its
had seen a nephrologist on or within 30 days of the indexmetabolites, and prescriptions for calcitriol and for cal-
date. We did so by searching for presence of specificcium-containing phosphate binders (CCPBs). We next ad-
specialty codes for nephrology associated with medicaldressed whether such care might help to explain changes
claims. Similarly, we ascertained the number of generalseen in mortality in the first year of RRT.
practitioner or family physician visits in 30 days prior
to index, the number of visits with internal medicine
METHODS specialists, as well as the number of hospital days during
We studied a cohort of 3014 incident RRT patients that time window.
enrolled in Medicare and in the New Jersey Pharmaceu- Other covariates describing important comorbidities
tical Assistance to the Aged and Disabled (PAAD) or were ascertained in a 90-day window: diabetes, hyperten-
New Jersey Medicaid programs between 1991 and mid- sion, coronary heart disease, congestive heart failure,
1996. Patients were required to have been enrolled and malignancy, and polycystic kidney disease. Race (Cauca-
active participants in these programs for more than 1 sian, African American, other) and gender were also
year prior to onset of RRT, and to have been diagnosed assessed. For the drug-related analyses, we required that
with CKD 1 year prior to RRT, to ensure that they at least one prescription had been filled in the 30 days
progressed to ESRD chronically rather than acutely. prior to the index date, as well as 30 days prior to the
Further selection steps were implemented to exclude index date to ensure that all subjects used were active
patients with likely acute renal failure from the cohort. in the system.
All patient identifiers were removed prior to analysis to For each set of analyses, we then built conditional
ensure patient confidentiality. The details of the selection logistic regression models, stratifying by risk set, with
algorithm have been published previously [31]. We then use of the respective laboratory test or prescription drug
extracted information on all hospitalizations, physician being the outcome. Independent covariates included prior
nephrologist consultation, the other health care utiliza-visits, procedures, and nursing home care received by
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Table 2. Care measures of calcium-phosphate metabolismTable 1. Characteristics of study cohorts
Overall Subgroup with Number of days prior to renal
replacement therapy (RRT)cohort prescription drug
(N  3014) coverage (N  1004) first recorded
Variable N % N % Interquartile
Care measure (N  %) Mean Median range
Age
45 83 2.8 33 3.3 Parathyroid hormone testing
(N  102; 3.4%) 525 465 (199–754)45–54 137 4.6 50 5.0
55–64 261 8.7 96 9.6 Vitamin D level testing
(N  10; 0.3%) 536 468 (280–730)65–74 1288 42.7 375 37.4
75–84 1063 35.3 378 37.7 First calcitriol prescription
(N  122; 12.2%) 376 269 (124–523)85 182 6.0 72 7.2
Gender First calcium-containing
phosphate-binder prescriptionFemale 1320 43.8 559 55.7
Male 1694 56.2 445 44.3 (N  161; 16.0%) 266 180 (77–421)
Race
Caucasian 2240 74.3 664 66.1
African American 586 19.4 291 29.0
Other 188 6.2 49 4.9
RESULTSDiabetes mellitus 1480 49.1 568 56.6
Polycystic kidney disease 157 5.2 54 5.4 Important characteristics of the full-study cohort and
Hypertension 2379 78.9 833 83.0
the subgroup of patients with drug benefits for 1 yearCongestive heart failure 1919 63.7 672 66.9
Coronary artery disease 2136 29.1 737 73.4 prior to first chronic RRT are shown in Table 1. Among
Malignancy 664 22.0 203 20.2 the 3014 patients in the full cohort, we found that 102
patients (3.4%) had iPTH measured prior to onset of
RRT, and only 10 patients (0.3%) had undergone labora-
tory assessment of blood levels of vitamin D or its metab-
tion covariates (general practitioner visit, internist visit, olites. In the subgroup of patients with pharmaceutical
hospital days), as well as race, gender, and the indicators benefits through the New Jersey PAAD or Medicaid pro-
grams (N  1004), 161 (16.0%) had filled a prescriptionfor diagnosis of comorbid conditions. It was decided a
of any CCPB and 122 (12.2%) had received calcitriol priorpriori to include race, gender, and all health care utiliza-
to onset of RRT. Only one patient received ergocalciferol,tion covariates in all models, as well as diabetes and
but only after having filled a prescription for calcitriol.polycystic kidney disease as important classes of renal
The timing of the first of each of the four care measurescomorbidity. Other comorbidities were included if they
in relation to the day of first RRT is shown in Table 2.remained significant at the P 0.25 level in multivariate
models (backward selection). We also tested for effect PTH testing
modification between nephrologist contact and patient
We successfully matched on age and number of days
age, as well as nephrologist contact and time between prior to RRT ( index day) 86 individuals had iPTH
index and first RRT. We calculated odds ratio (OR) as levels measured and 448 controls. Univariate conditional
the measure of association, and 95% confidence intervals logistic regression models indicated that tested patients
(95% CI). were 68% more likely to have seen a nephrologist over
For the second part of the analysis, we expanded on the the preceding 30 days than controls (OR 1.68; 95% CI,
Cox proportional hazards models published in previous 1.02 to 2.76). Utilization of general practitioner services,
work [7], where death was the event of interest, and cen- internists, or hospital days over that time window were
not different among cases and controls (Table 3). Multi-sored patients at the earliest of the following: transplanta-
variate conditional logistic models controlling for demo-tion, loss to follow-up, or end of database. In addition to
graphic characteristics and comorbid conditions revealedage, gender, race, and certain comorbidities (hyperten-
that tested patients were more than twice as likely tosion, diabetes, congestive heart failure, coronary artery
have seen a nephrologist during the previous month com-disease, malignancy), we included a variable depicting
pared to patients who did not have testing for iPTH atlate versus early nephrologist referral (90 days vs.90
the same number of days prior to RRT (OR 2.26; 95%
days prior to RRT) and/or a covariate indicating whether CI, 1.35 to 3.80). Other health care utilization covariates
a patient had received any of the four care measures were not associated with case vs. control status.
of interest prior to RRT (iPTH, vitamin D assessment,
Vitamin D testingcalcitriol, or CCPB prescription). For those, we calcu-
lated hazards ratio (HR) as the measure of association, Only 10 patients had laboratory assessment of vitamin
and corresponding 95% CI. We used SAS 8.1 (The SAS D status prior to RRT, precluding any meaningful statis-
tical analyses.Corporation, Cary, NC, USA) for all statistical analyses.
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Table 3. Factors associated with first parathyroid hormone testing (N  3014)
Conditional logistic regression matched on age and time to renal replacement therapy (RRT)
Univariate results Multivariate results
Odds 95% Confidence Odds 95% Confidence
Variable ratio interval P value ratio interval P value
Nephrologist visit 1.68 1.02–2.76 0.04 2.27 1.35–3.80 0.002
General practitioner visit 0.70 0.25–2.01 0.51 0.81 0.27–2.37 0.69
Internal medicine visit 0.66 0.36–1.21 0.18 0.76 0.41–1.41 0.38
Hospitalization 0.45 0.14–1.44 0.18 0.52 0.15–1.77 0.29
Female 1.0 (referent) — 1.0 (referent) —
Male 1.17 0.72–1.89 0.54 1.32 0.80–2.17 0.28
Caucasian 1.0 (referent) — 1.0 (referent) —
African American 1.23 0.67–2.26 0.52 1.35 0.72–2.51 0.35
Other 4.36 2.34–8.14 0.001 4.28 2.33–8.24 0.001
Diabetes mellitus 0.37 0.20–0.70 0.002 0.41 0.22–0.80 0.008
Polycystic kidney disease 0.76 0.18–3.20 0.71 0.88 0.21–3.72 0.86
Hypertension 0.65 0.38–1.10 0.11 NE — —
Congestive heart failure 0.60 0.31–1.17 0.13 NE — —
Coronary artery disease 0.60 0.35–1.01 0.05 NE — —
Malignancy 0.47 0.15–1.51 0.20 NE — —
NE is not estimated. Parameter was eliminated from final model (P value  0.25).
Table 4. Factors associated with filling a first prescription for calcitriol (N  1004)
Conditional logistic regression matched on age and time to renal replacement therapy (RRT)
Univariate results Multivariate results
Odds 95% Confidence Odds 95% Confidence
Variable ratio interval P value ratio interval P value
Nephrologist visit 6.25 3.97–9.84 0.001 5.13 3.17–8.32 0.001
General practitioner visit 1.47 0.73–2.97 0.29 1.13 0.52–2.49 0.75
Internal medicine visit 0.86 0.54–1.38 0.54 1.07 0.64–1.77 0.80
Hospitalization 3.20 2.08–4.91 0.001 2.81 1.59–4.98 0.001
Female 1.0 (referent) — — (referent) —
Male 0.73 0.47–1.12 0.15 0.68 0.42–1.10 0.11
Caucasian 1.0 (referent) — — (referent) —
African American 1.17 0.74–1.86 0.50 1.16 0.71–1.90 0.56
Other 1.14 0.41–3.17 0.80 0.85 0.27–2.72 0.79
Diabetes mellitus 1.39 0.90–2.14 0.14 1.05 0.65–1.69 0.85
Polycystic kidney disease 0.35 0.08–1.46 0.15 0.31 0.07–1.44 0.13
Hypertension 1.25 0.82–1.89 0.31 NE — —
Congestive heart failure 0.90 0.56–1.44 0.65 0.42 0.23–0.76 0.004
Coronary artery disease 0.98 0.63–1.52 0.92 NE — —
Malignancy 0.96 0.48–1.90 0.90 NE — —
NE is not estimated. Parameter was eliminated from final model (P value  0.25).
Calcitriol prescriptions visit increased the odds of receiving the drug fivefold over
patients who had not seen a nephrologist (OR  5.13;As above, we matched on age and index day 102 pa-
95% CI, 3.17 to 8.32). Prior hospitalization was alsotients who filled a prescription for calcitriol and 409 CKD
predictive of starting calcitriol therapy (OR 2.81; 95%patients who had not done so. Univariate analyses showed
CI, 1.59 to 4.98).that recipients of calcitriol were more than six times as
likely to have seen a nephrologist over the previous month
CCPB prescriptionsthan nonrecipients of this medication (OR  6.25; 95%
For this analysis, we were able to match 99 recipients ofCI, 3.97 to 9.84) (see Table 4). As before, visits with
CCPBs with 426 control patients. The univariate modelsgeneral practitioners or internists were not associated with
showed that recipients of a CCPB were 6.5 times as likelyreceipt of the medication. Hospitalization during the pre-
to have seen a nephrologist within 30 days prior to fillingvious 30 days also made patients more likely to have
their first prescription than were nonrecipients of thereceived calcitriol (OR  3.20; 95% CI, 2.08 to 4.91).
drug (OR  6.46; 95% CI, 4.03 to 10.36) (Table 5).The effect of nephrologist visits on the likelihood of
Neither of the other physician visit covariates demon-filling a prescription for calcitriol remained robust in
multivariate models. Having had a prior nephrologist strated such a univariate association with receipt of a
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Table 5. Factors associated with filling a first prescription for a calcium-containing phosphate binder (CCPB) (N  1004)
Conditional logistic regression matched on age and time to renal replacement therapy (RRT)
Univariate results Multivariate results
Odds 95% Confidence Odds 95% Confidence
Variable ratio interval P value ratio interval P value
Nephrologist visit 6.46 4.03–10.36 0.001 6.60 3.97–10.96 0.001
General practitioner visit 1.26 0.61–2.59 0.53 1.45 0.66–3.16 0.36
Internal medicine visit 1.15 0.73–1.81 0.55 1.36 0.83–2.22 0.22
Hospitalization 2.41 1.54–3.77 0.001 1.19 0.72–1.96 0.50
Female 1.0 (referent) — 1.0 (referent) —
Male 0.80 0.52–1.23 0.31 0.72 0.46–1.14 0.16
Caucasian 1.0 (referent) — 1.0 (referent) —
African American 0.68 0.41–1.12 0.13 0.61 0.36–1.02 0.06
Other 0.69 0.16–3.05 0.63 0.73 0.13–4.14 0.72
Diabetes mellitus 1.13 0.74–1.75 0.57 1.12 0.71–1.75 0.64
Polycystic kidney disease 0.84 0.29–2.40 0.73 0.80 0.23–2.72 0.72
Hypertension 1.50 0.97–2.30 0.07 NE — —
Congestive heart failure 0.92 0.59–1.42 0.69 NE — —
Coronary artery disease 1.07 0.70–1.63 0.77 NE — —
Malignancy 0.92 0.44–1.96 0.83 NE — —
NE is not estimated. Parameter was eliminated from final model (P value  0.25).
Table 6. Effect estimates of the multivariate Cox proportionalCCPB, but prior hospitalization was associated with a
hazards models of 1-year survival on renal replacement therapy (RRT)
higher likelihood of receiving the compound (OR 2.41;
Odds 95% Confidence95% CI, 1.54 to 3.77). The univariate association be-
Modela ratio interval P valuetween nephrologist visit and prescription of CCPB re-
Late vs. early referral only 1.31 1.08–1.58 0.006mained stable in multivariate analyses (OR  6.60; 95%
Presence of any calcium-
CI, 3.97 to 10.95), but the effect of prior hospitalization phosphate care measure
prior to first RRT only 0.62 0.49–0.80 0.001did not (Table 5).
Late vs. early referral and 1.22 1.00–1.48 0.05
Presence of any calcium-Effect of management of calcium-phosphate
phosphate care measure
metabolism on 1-year mortality prior to first RRT 0.65 0.51–0.84 0.001
aAll models controlled for age, gender, race (Caucasian, African American,Next, we evaluated whether presence of any calcium-
other), hypertension, diabetes, coronary artery disease, congestive heart failure,phosphate care indicator was associated with mortality malignancy
in the first year of RRT. Using the 1004 patients with
drug coverage, we first built a model similar to the one
we published previously [11] and confirmed that late
rather than early nephrologist referral (90 vs.90 days
DISCUSSIONprior to RRT) was associated with a 31% higher mortal-
We evaluated several measures of calcium-phosphateity rate (HR 1.31; 95% CI, 1.08 to 1.58) in these patients
metabolism care (laboratory assessment of iPTH andafter controlling for age, gender, race, presence of hyper-
vitamin D levels and prescription of calcitriol or CCPBs)tension, coronary artery disease, congestive heart failure,
in a cohort of patients with progressing CKD beforeand malignancy (Table 6). When replacing the late refer-
onset of RRT. In contrast to recent studies that high-ral covariate with an indicator for any of the four care
lighted the high prevalence of disturbances in the cal-measures studied herein, we found that the presence of
cium-phosphate metabolism at relatively early stages ofone or more of these care indicators (iPTH or vitamin
CKD [13, 17], we found each of the four care measuresD measurement, or a prescription for calcitriol or any
were performed in only a small proportion of patients.CCPB) was associated with a 38% reduction in the likeli-
Only 3.4% of patients were tested for levels of iPTH, andhood of death in the first year of RRT compared to those
vitamin D was assessed in even fewer patients (0.3%).who did not receive such care (HR  0.62; 95% CI, 0.49
Approximately 12.2% of patients filled a prescriptionto 0.80). When including both the late referral covariate
for calcitriol prior to RRT and 16% for any CCPB. Weand the calcium-phosphorus care indicator covariate in
found a strong and temporally close relationship be-the same model, the effect of the latter did not change
tween presence of a nephrologist visit and iPTH testing(HR  0.65; 95% CI, 0.51 to 0.84); however, the effect
(OR  2.27; 95% CI, 1.35 to 3.80), patients’ filling pre-of late referral on mortality was attenuated (HR  1.22;
95% CI, 1.00 to 1.48). scriptions for calcitriol (OR 5.13; 95% CI, 3.17 to 8.32)
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and use of CCPBs (OR  6.60; 95% CI, 3.97 to 10.96). possibilities will have to be subjected to careful analysis.
Creative thinking and considerable experimentation willBy contrast, we did not find any such associations be-
be required to define the optimal mix of specialist-gener-tween prior general practitioner care, or with prior visits
alist involvement in the care of such patients.with a nonnephrologist internist. These results indicate
There are certain limitations to our study. Our analy-strongly that nephrologists, rather than generalists or
ses are based on large claims databases that may beinternists of other subspecialties, are responsible for im-
prone to miscoding or misclassification. It can be as-portant domains of calcium-phosphate metabolism care
sumed, however, that such misclassification will occurin patients with CKD. The interval between the first
randomly rather than systematically, and, therefore, biasprescription for calcitriol and the initiation of RRT was
any results toward the null. Furthermore, it is possibleconsiderably longer than that between the first prescrip-
that we cannot capture all events of iPTH or vitamintion of a CCPB and the start of dialysis. Although the
D testing, if some patients were hospitalized when itcurrent study was not designed to address issues of
occurred. This would lead to an underestimation of thepathophysiology, the findings suggest that disturbances
true percentage of patients screened. Similar biases arethat lead to vitamin D therapy, such as hypocalcemia
not possible with the drug-based analyses because pa-and/or elevated plasma PTH levels, occur earlier in the
tients would fill a prescription right after discharge fromcourse of progressive renal failure than those that trigger
hospital care. However, there is the possibility that pa-that use of phosphate-binding medications.
tients obtained over-the-counter preparations of calciumIn studying 1-year mortality, we found that calcium-
carbonate, which would be unaccounted for in our study.phosphate care interventions were associated with a 38%
Also, we do not have any clinical information such aslower mortality on RRT compared to patients who did
blood levels of biologic markers. It is possible that pa-not receive such attention of their calcium-phosphate me-
tients who received the care measures under study maytabolism (OR  0.62; 95% CI, 0.49 to 0.80). All models
have had more serious disease. However, patients whoaccounted for baseline differences in age, gender, race,
received calcium-phosphate metabolism care prior toand important comorbidities. These findings suggest that
first RRT had better survival compared to their counter-management of calcium-phosphate metabolism is an im-
parts of similar age, demographics, and comorbidity. Weportant mediator of the beneficial effect on mortality
cannot rule out the possibility that rather than being theseen with timely nephrologist care in patients with CKD.
cause of the reduction in mortality noted, such care mayThese results have important policy implications. First,
have been a marker for overall higher quality of care,specific care measures pertaining to calcium-phosphate
and/or for patients who were more compliant or other-metabolism occur in a surprisingly small fraction of CKD
wise attentive to their medical regimens.patients compared to what would be expected given cross-
We conclude that there is considerable room for im-sectional data about the frequency of such disturbances
provement in the care of patients with CKD regarding[13, 34]. Second, our data indicate that management of
their management of calcium-phosphate metabolism.calcium-phosphate metabolism in patients with CKD is
Nephrologist consultation is associated with a higher fre-predominantly nephrologist-driven. Third, we were able
quency of use of laboratory and pharmaceutical mea-to demonstrate a strong association between calcium-
sures to manage this problem, and patients who receivephosphate metabolism care and improved mortality on
such care of calcium-phosphate metabolism experienceRRT. Improving this care domain in patients with CKD
lower mortality once they initiate RRT. Given the man-may yield improved outcomes among patients on RRT,
power limitations of available nephrologists, it seemsprobably even in patients with (advanced) CKD. This
prudent to train nonnephrologists in managing this meta-
hypothesis needs to be tested in further research.
bolic disorder. Further research is necessary to confirm
If this conclusion holds true, then it raises important
our findings and to develop quality improvement pro-
questions about how best to care for all these patients.
grams to further the medical management of the vulnera-
Nephrologist manpower projections for the care of patients ble population of patients with progressing CKD.
on RRT alone are already falling short of the expected
number of nephrologists available. It may be that educa-
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